{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001062822","name":"LEXICON PHARMACEUTICALS, INC.","summary":"Lexicon Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines. Its approved drug INPEFA (sotagliflozin) reduces cardiovascular death risk in heart failure patients. It is developing sotagliflozin for hypertrophic cardiomyopathy (HCM) and type 1 diabetes, pilavapadin for neuropathic pain, and LX9851 for obesity, the latter licensed exclusively to Novo Nordisk. The company uses gene knockout technologies to identify drug targets.","people":[],"products":[{"name":"INPEFA (sotagliflozin)","type":"platform","description":"FDA-approved once-daily oral tablet to reduce cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors."},{"name":"sotagliflozin (HCM)","type":"platform","description":"Orally-delivered small molecule in Phase 3 SONATA-HCM trial for hypertrophic cardiomyopathy."},{"name":"ZYNQUISTA (sotagliflozin)","type":"platform","description":"Sotagliflozin being pursued for regulatory approval as adjunct to insulin for glycemic control in adults with type 1 diabetes and CKD."},{"name":"pilavapadin (LX9211)","type":"platform","description":"Orally-delivered small molecule AAK1 inhibitor in development for neuropathic pain, specifically diabetic peripheral neuropathic pain; has FDA Fast Track designation."},{"name":"LX9851","type":"platform","description":"Orally-delivered small molecule licensed exclusively to Novo Nordisk for development and commercialization as a treatment for obesity and associated cardiometabolic disorders."}],"partnerships":[{"partner_name":"Novo Nordisk","partnership_type":"licensing","description":"Exclusive, worldwide, royalty-bearing license granted to Novo Nordisk to develop, manufacture, and commercialize LX9851 for obesity and cardiometabolic disorders.","start_date":null},{"partner_name":"Bristol-Myers Squibb","partnership_type":"development","description":"Collaborative neuroscience drug discovery alliance from which pilavapadin originated; Lexicon holds exclusive development and commercialization rights.","start_date":null}],"affiliations":[],"origin":{"leaf":"7f7709a79b5cf4cb4dec7aab43d84c16cd29730e0a0d06268bdd56bba9f5c89b","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"737c3b5c73beabdf6534d9a40e527b403c4ee60a7019d8d47cac5624adbadcb1","parent":"42f980057c4478d0097151f68ed380facec66fd24102320a571cb3a4ea5b1710","source":"0001062822-26-000050","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":108,"hourly_limit":500,"remaining":392,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}